Name: 글로벌 시장 동향
SKU: PH7357
Availability: InStock

보고서 요약(국문)

개요
전 세계 미만성 피부 전신 경화증(DcSSc) 치료제 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
미만성 피부 전신 경화증(DcSSc)은 전신 경화증(전신 경화증)의 한 유형으로, 피부 경화(섬유화)와 신체 여러 장기의 문제를 특징으로 합니다. 이 질환은 어느 연령에서든 발생할 수 있지만 주로 40~50세 사이의 사람들에게 영향을 미칩니다. 구강 건조증과 치아 문제가 발생할 수 있으며, 관절통, 근육통, 근력 약화, 경련, 손가락이나 발가락 끝의 골용해(acroosteolysis) 등이 흔하게 나타납니다. 심각한 경우 폐 섬유증이나 폐 고혈압, 신장 문제도 발생할 수 있습니다.
또한, 이 질환의 정확한 원인은 아직 알려지지 않았습니다. 미만성 피부 전신 경화증(DcSSc)에 대한 완치법은 현재 없습니다. 치료는 증상에 따라 다르지만 약물 치료와 수술이 포함될 수 있습니다. 레이노 현상은 칼슘 채널 차단제로 치료할 수 있습니다. 위식도 역류에는 양성자 펌프 억제제가 투여됩니다. 심한 석회화증의 경우 외과적 절제가 필요할 수 있습니다. 최근 심한 피부 병변이 발생했거나 폐 섬유증이 진행된 경우에는 저용량 코르티코스테로이드와 면역억제제를 병용해야 합니다. 폐동맥 고혈압의 경우에는 폐혈관 확장제를 투여합니다.
시장 동향: 성장 요인
혁신적인 신약에 대한 수요 증가
미만성 피부 전신 경화증 치료를 위한 혁신적인 신약에 대한 수요 증가가 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 기존의 DcSSc 치료법은 효과가 충분하지 않거나 심각한 부작용을 동반하기 때문에 이러한 미충족 의료 수요를 해결할 수 있는 혁신적인 신약에 대한 수요가 높습니다. 혁신적인 신약들은 미만성 피부 전신 경화증(DcSSc) 관리에 있어 충족되지 않은 요구를 해결하고, 질병 관리를 위한 대안 또는 보완적인 치료 옵션을 제공하는 것을 목표로 합니다.
또한, 미만성 피부 전신 경화증 치료에 더 나은 결과를 보이는 혁신적인 신약 개발을 위한 많은 임상 시험이 진행 중입니다. 신약의 효능과 안전성을 평가하는 임상 시험에서 긍정적인 결과가 나오면 수요가 증가할 수 있습니다. 만약 새로운 약물이 임상 연구에서 DcSSc 치료에 상당한 개선 효과를 보인다면, 그 사용이 증가할 가능성이 높습니다.
예를 들어, 2023년 2월 21일, 미충족 수요가 높은 섬유염증성 질환에 대한 혁신적인 치료제 발굴 및 개발에 주력하는 임상 단계 생명공학 기업인 케모mAb Ltd.는 미만성 피부 전신 경화증 성인 환자를 대상으로 CM-101의 2상 임상 시험을 평가하기 위한 임상시험계획(IND) 신청에 대해 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다.

또한, 미만성 피부 전신 경화증(DcSSc)의 유병률 증가, FDA 승인 증가, 임상 시험 증가, 약물 이용 가능성에 대한 인식 제고 및 신약 개발의 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
제약 요인
고용량 약물 투여와 관련된 합병증, 일부 치료제의 높은 가격, 적절한 치료법의 부족, 대체 치료법의 존재 등은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 미만성 피부 전신 경화증(DcSSc) 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
면역억제제 부문은 미만성 피부 전신 경화증(DcSSc) 치료제 시장 점유율의 약 39.3%를 차지했습니다.
면역억제제는 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 일반적으로 이 질환은 완치할 수 없지만, 마이코페놀레이트 모페틸, 메토트렉세이트, 사이클로포스파미드, 리툭시맙, 토실리주맙 등의 면역억제제가 미만성 피부 전신 경화증 치료에 가장 흔히 사용됩니다.
미만성 피부 전신 경화증의 유병률이 증가함에 따라 면역억제제 사용에 대한 수요도 지속적으로 증가하고 있습니다. 예를 들어, 미국 희귀질환기구(National Organization for Rare Disorders)에 따르면, 미만성 피부 전신 경화증을 포함한 전신 경화증은 약 1만 명 중 1명꼴로 발생합니다. 이 질환은 여성에게 더 흔하며, 대부분 30~50세 사이에 발병합니다.
또한, 메토트렉세이트는 미만성 피부 전신 경화증을 포함한 자가면역 질환 치료에 흔히 사용됩니다. 메토트렉세이트는 염증을 줄이고 면역 반응을 조절하는 데 도움을 줄 수 있습니다. 마이코페놀레이트 모페틸(Mycophenolate Mofetil) 면역억제제는 DcSSc 치료에 사용되는 또 다른 선택지입니다. 이는 면역 세포의 증식을 억제하는 방식으로 작용합니다. 리툭시맙(Rituximab)은 면역 체계의 특정 B 세포를 표적으로 합니다. B 세포가 중요한 역할을 하는 DcSSc 환자에게 사용될 수 있습니다. 또한, 이러한 면역억제제의 광범위한 사용은 수요 증가로 이어지고 있습니다.
지역 분석
북미는 시장 점유율의 약 40.1%를 차지했습니다.
북미 지역은 주요 제약 회사와 선진 의료 시설의 강력한 입지로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 북미, 특히 미국은 제약 회사 및 생명 공학 회사와 같은 주요 기업들의 강력한 존재로 잘 알려져 있습니다. 이러한 주요 기업들의 활발한 활동은 신약 개발을 위한 임상 시험에 기여하고 있습니다.

예를 들어, 2021년 11월 9일, 호라이즌 테라퓨틱스(Horizon Therapeutics plc)는 개발 단계에 있는 약물 HZN-825(리소포스파티드산 수용체 1(LPAR1) 길항제)의 2b상 핵심 임상시험에 첫 환자가 등록했다고 발표했습니다. HZN-825는 전신 경화증(경피증이라고도 함)의 하위 유형인 미만성 피부 전신 경화증 환자를 치료하기 위한 것입니다.
또한, 이 지역은 병원, 전문 클리닉, 학술 및 연구 기관과 같은 선진 의료 인프라로 매우 잘 알려져 있으며, 이러한 시설에서는 새롭고 더 나은 약물을 사용하여 미만성 피부 전신 경화증에 대한 선진 치료 시설을 제공함으로써 환자 예후를 개선하고 있습니다. 연구 및 학술 기관은 항상 혁신적인 약물 개발을 위한 연구 활동에 집중합니다.
경쟁 환경
전 세계 주요 미만성 피부 전신 경화증(DcSSc) 치료제 시장 업체로는 루핀 제약(Lupin Pharmaceuticals, Inc.), 바이엘(Bayer AG), 제넨텍(Genentech, Inc.), 화이자(Pfizer Inc.), 주빌런트 카디스타 제약(Jubilant Cadista Pharmaceuticals Inc.), 코버스 제약 홀딩스(Corbus Pharmaceuticals Holdings, Inc.), 호라이즌 테라퓨틱스(Horizon Therapeutics plc), 글락소스미스클라인(GlaxoSmithKline plc), F. 호프만-라로슈(F. Hoffmann-La Roche Ltd), 카드몬 제약(Kadmon Pharmaceuticals, LLC) 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 미만성 피부 전신 경화증(DcSSc) 치료제 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 다양한 치료 분야의 임상 시험이 중단되었으며, 새로운 DcSSc 치료제 또는 적응증 확대를 연구하는 임상 시험은 COVID-19 팬데믹 대응에 집중되면서 일시적으로 지연되었습니다. 이는 약물 개발 및 규제 승인 일정에 영향을 미쳤습니다. 팬데믹은 또한 이러한 치료제의 전 세계적인 공급망을 교란시켰습니다.
시장 세분화
약물 종류별
• 칼슘 채널 차단제
o 니페디핀
o 암로디핀
o 기타
• 면역억제제
o 미코페놀레이트 모페틸
o 메토트렉세이트
o 시클로포스파미드
o 리툭시맙
o 토실리주맙
o 기타
• 폐혈관 확장제
o 펜톡시필린
o 니트로글리세린
o 기타
• 프로톤 펌프 억제제
• 포스포디에스테라제 억제제 (실데나필)
• 코르티코스테로이드
• 기타
투여 경로별
• 경구
• 피하
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미 • 아메리카
• 브라질
• 아르헨티나
• 기타 남미
• 아시아 태평양
• 중국
• 인도
• 일본
• 호주
• 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 약물 종류, 투여 경로, 유통 채널 및 지역별 전 세계 미만성 피부 경화증 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 미만성 피부 경화증 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

전 세계 미만성 피부 경화증 치료제 시장 보고서는 약 61개의 표, 61개의 그림, 그리고 187페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global diffuse cutaneous systemic sclerosis(DcSSc) drugs market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Diffuse cutaneous systemic sclerosis (DcSSc) is a subtype of systemic scleroderma (systemic sclerosis) characterized by skin hardening (fibrosis) and problems in many organs of the body. The disease can occur at any age but mainly affects people between 40 and 50 years of age. Dry mouth and dental involvement can occur. Joint pain (arthralgias), muscular pain, weakness, cramps, and destruction of the tips of the fingers or toes (acroosteolysis) are frequent. Severe problems involving the lung (fibrosis or pulmonary hypertension) and kidney problems may also occur.
Moreover, the exact cause of the condition is unknown. There is currently no cure for diffuse cutaneous systemic sclerosis. Treatment depends on the symptoms but may include medication and surgery. Raynaud's phenomenon can be treated with calcium channel blockers. Proton pump inhibitors are given for gastric reflux. Surgical resection of severe calcinosis may be required. Low doses of corticosteroids with immunosuppressive agents are needed in cases with recent severe cutaneous involvement or in progressive lung fibrosis. Pulmonary vasodilators are given in case of pulmonary arterial hypertension.
Market Dynamics: Drivers
Increasing demand for innovative drugs
The increasing demand for innovative drugs for the treatment of diffuse cutaneous systemic sclerosis is expected to drive the market over the forecast period. The existing treatments for DcSSc are not fully effective or have significant side effects, there is a high demand for innovative drugs that can address these unmet medical needs. The innovative drugs aim to address the unmet needs associated with the management of diffuse cutaneous systemic sclerosis by providing alternative or complementary treatment options for better disease management.
Moreover, many clinical trials are going on for the development of innovative drugs that show better results in diffuse cutaneous systemic sclerosis treatment. Positive results from clinical trials evaluating the efficacy and safety of new drugs can boost demand. If a novel drug demonstrates significant improvements in treating DcSSc in clinical studies, it is likely to increase the adoption.
For instance, on February 21, 2023, ChemomAb Ltd., a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, released the U.S. Food and Drug Administration (FDA) clearance of the company's Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with diffuse cutaneous systemic sclerosis.
Further, the increasing prevalence of the diffuse cutaneous systemic sclerosis, rising FDA approvals, increasing clinical trials, increasing awareness about the drug's availability and advancements in developing novel drugs are expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the high doses of drugs, the high cost of some treatment drugs, lack of appropriate treatment and the availability of alternative treatment options are expected to hamper the market.
Segment Analysis
The global diffuse cutaneous systemic sclerosis(DcSSc) drugs market is segmented based on drug class, route of administration, distribution channel and region.
The immunosuppressives segment accounted for approximately 39.3% of the diffuse cutaneous systemic sclerosis(DcSSc) drugs market share
The immunosuppressive agents are expected to hold the largest market share over the forecast period. Usually, there is no cure for this disease, but immunosuppressives such as mycophenolate mofetil, methotrexate, cyclophosphamide, rituximab, tocilizumab and other immunosuppressives are most commonly used for the treatment of the diffuse cutaneous systemic sclerosis.
Due to the rising prevalence of the diffuse cutaneous systemic sclerosis, the demand for the use of immunosuppressives is continuously increasing. For instance, according to the National Organization for Rare Disorders, approximately one in 10,000 individuals is affected with systemic sclerosis including diffuse cutaneous systemic sclerosis. It is more common in women and most often develops around age 30 to 50.
Further, methotrexate is commonly used in the treatment of autoimmune diseases, including DcSSc. Methotrexate can help reduce inflammation and modify the immune response. Mycophenolate Mofetil immunosuppressant is another option that is used to treat DcSSc. It works by inhibiting the proliferation of immune cells. Rituximab targets specific B cells in the immune system. It may be used in cases of DcSSc where B cells play a significant role. In addition, their wide adoption also increases the demand for immunosuppressives.
Geographical Analysis
North America accounted for approximately 40.1% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and biotechnology companies. This strong presence of major players actively performs in clinical trials for the development of novel drugs.
For instance, on November 9, 2021, Horizon Therapeutics plc released that the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with diffuse cutaneous systemic sclerosis, a subset of systemic sclerosis (also known as scleroderma).
Furthermore, the region is also very well known for its advanced healthcare infrastructure such as hospitals, specialty clinics and academic and research institutes which provide advanced treatment facilities for diffuse cutaneous systemic sclerosis by using novel and better drugs which results in better patient outcomes. The research and academic institutes always focus on the research activities for the development of the innovative drugs
Competitive Landscape
The major global players in the diffuse cutaneous systemic sclerosis (DcSSc) drugs market include Lupin Pharmaceuticals, Inc., Bayer AG, Genentech, Inc., Pfizer Inc., Jubilant Cadista Pharmaceuticals Inc., Corbus Pharmaceuticals Holdings, Inc., Horizon Therapeutics plc, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Kadmon Pharmaceuticals, LLC. And among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global diffuse cutaneous systemic sclerosis (DcSSc) drugs market. The pandemic led to disruptions in clinical trials across various therapeutic areas, including for new DcSSc drugs or those investigating expanded indications may have faced delays temporarily due to the redirected focus towards the COVID-19 pandemic, this results in impacting timelines for drug development and regulatory approvals. The pandemic also disrupted the supply chain of these treatment drugs globally.
Market Segmentation
By Drug Class
• Calcium Channel Blockers
o Nifedipine
o Amlodipine
o Others
• Immunosuppressive Agents
o Mycophenolate Mofetil
o Methotrexate
o Cyclophosphamide
o Rituximab
o Tocilizumab
o Others
• Pulmonary Vasodilators
o Pentoxifylline
o Nitroglycerin
o Others
• Proton Pump Inhibitors
• Phosphodiesterase Inhibitors (Sildenafil)
• Corticosteroids
• Others
By Route Of Administration
• Oral
• Subcutaneous
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global diffuse cutaneous systemic sclerosis drugs market segmentation based on drug class, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of diffuse cutaneous systemic sclerosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global diffuse cutaneous systemic sclerosis drugs market report would provide approximately 61 tables, 61 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Innovative Drugs
4.1.2. Restraints
4.1.2.1. Side Effects Associated with the Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. Volume Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Calcium Channel Blockers*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Nifedipine
7.2.4. Amlodipine
7.2.5. Others
7.3. Immunosuppressive Agents
7.3.1. Mycophenolate Mofetil
7.3.2. Methotrexate
7.3.3. Cyclophosphamide
7.3.4. Rituximab
7.3.5. Tocilizumab
7.3.6. Others
7.4. Pulmonary Vasodilators
7.4.1. Pentoxifylline
7.4.2. Nitroglycerin
7.4.3. Others
7.5. Proton Pump Inhibitors
7.6. Phosphodiesterase Inhibitors (Sildenafil)
7.7. Corticosteroids
7.8. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Lupin Pharmaceuticals, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Bayer AG
12.3. Genentech, Inc.
12.4. Pfizer Inc.
12.5. Jubilant Cadista Pharmaceuticals Inc.
12.6. Corbus Pharmaceuticals Holdings, Inc.
12.7. Horizon Therapeutics plc
12.8. GlaxoSmithKline plc
12.9. F. Hoffmann-La Roche Ltd
12.10. Kadmon Pharmaceuticals, LLC.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Lupin Pharmaceuticals, Inc., 4.	Key Developments, Bayer AG, Genentech, Inc., Pfizer Inc., Jubilant Cadista Pharmaceuticals Inc., Corbus Pharmaceuticals Holdings, Inc., Horizon Therapeutics plc, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Kadmon Pharmaceuticals, LLC.

표 목록 (Tables)

List of Tables

Table 1 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 7 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 14 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Lupin Pharmaceuticals, Inc.: Overview

Table 33 Lupin Pharmaceuticals, Inc.: Product Portfolio

Table 34 Lupin Pharmaceuticals, Inc.: Key Developments

Table 35 Bayer AG: Overview

Table 36 Bayer AG: Product Portfolio

Table 37 Bayer AG: Key Developments

Table 38 Genentech, Inc.: Overview

Table 39 Genentech, Inc.: Product Portfolio

Table 40 Genentech, Inc.: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Jubilant Cadista Pharmaceuticals Inc.: Overview

Table 45 Jubilant Cadista Pharmaceuticals Inc.: Product Portfolio

Table 46 Jubilant Cadista Pharmaceuticals Inc.: Key Developments

Table 47 Corbus Pharmaceuticals Holdings, Inc.: Overview

Table 48 Corbus Pharmaceuticals Holdings, Inc.: Product Portfolio

Table 49 Corbus Pharmaceuticals Holdings, Inc.: Key Developments

Table 50 Horizon Therapeutics plc: Overview

Table 51 Horizon Therapeutics plc: Product Portfolio

Table 52 Horizon Therapeutics plc: Key Developments

Table 53 GlaxoSmithKline plc: Overview

Table 54 GlaxoSmithKline plc: Product Portfolio

Table 55 GlaxoSmithKline plc: Key Developments

Table 56 F. Hoffmann-La Roche Ltd: Overview

Table 57 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 58 F. Hoffmann-La Roche Ltd: Key Developments

Table 59 Kadmon Pharmaceuticals, LLC.: Overview

Table 60 Kadmon Pharmaceuticals, LLC.: Product Portfolio

Table 61 Kadmon Pharmaceuticals, LLC.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 2 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Calcium Channel Blockers Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 8 Immunosuppressive Agents Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 9 Pulmonary Vasodilators Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 10 Proton Pump Inhibitors Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 11 Phosphodiesterase Inhibitors (Sildenafil) Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 12 Corticosteroids Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 13 Others Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 14 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 15 Oral Route of Administration in Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 16 Subcutaneous Route of Administration in Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 17 Others Route of Administration in Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 18 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacies Distribution Channel in Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 20 Retail Pharmacies Distribution Channel in Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 21 Online Pharmacies Distribution Channel in Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 22 Global Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 26 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 28 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 29 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 30 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 31 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32 North America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 34 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 35 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 South America Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 39 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 40 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Europe Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 44 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 45 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 Asia-Pacific Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 48 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Value, 2021-2030 (US$ Million)

Figure 49 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 50 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Middle East & Africa Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 Lupin Pharmaceuticals, Inc.: Financials

Figure 53 Bayer AG: Financials

Figure 54 Genentech, Inc.: Financials

Figure 55 Pfizer Inc.: Financials

Figure 56 Jubilant Cadista Pharmaceuticals Inc.: Financials

Figure 57 Corbus Pharmaceuticals Holdings, Inc.: Financials

Figure 58 Horizon Therapeutics plc: Financials

Figure 59 GlaxoSmithKline plc: Financials

Figure 60 F. Hoffmann-La Roche Ltd: Financials

Figure 61 Kadmon Pharmaceuticals, LLC.: Financials

전 세계 미만성 피부 전신 경화증(DCSc) 치료제 시장 – 2023-2030

Global Diffuse cutaneous systemic sclerosis(DcSSc) Drugs Market - 2023-2030